A detailed history of Geode Capital Management, LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,863,667 shares of VKTX stock, worth $99.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,863,667
Previous 1,859,082 0.25%
Holding current value
$99.6 Million
Previous $98.5 Million 19.73%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$49.84 - $70.47 $228,516 - $323,104
4,585 Added 0.25%
1,863,667 $118 Million
Q2 2024

Aug 09, 2024

SELL
$47.39 - $80.2 $22.2 Million - $37.5 Million
-467,697 Reduced 20.1%
1,859,082 $98.5 Million
Q1 2024

May 13, 2024

BUY
$17.4 - $94.5 $3.45 Million - $18.8 Million
198,436 Added 9.32%
2,326,779 $191 Million
Q4 2023

Feb 13, 2024

BUY
$9.24 - $19.64 $938,368 - $1.99 Million
101,555 Added 5.01%
2,128,343 $39.6 Million
Q3 2023

Nov 13, 2023

BUY
$10.92 - $16.0 $1.97 Million - $2.89 Million
180,349 Added 9.77%
2,026,788 $22.4 Million
Q2 2023

Aug 11, 2023

BUY
$14.84 - $24.79 $14.6 Million - $24.4 Million
983,207 Added 113.9%
1,846,439 $29.9 Million
Q1 2023

May 15, 2023

BUY
$8.08 - $17.33 $1.69 Million - $3.62 Million
208,926 Added 31.93%
863,232 $14.4 Million
Q4 2022

Feb 13, 2023

BUY
$2.72 - $9.4 $3,451 - $11,928
1,269 Added 0.19%
654,306 $6.15 Million
Q3 2022

Nov 14, 2022

SELL
$2.55 - $3.89 $83,415 - $127,249
-32,712 Reduced 4.77%
653,037 $1.78 Million
Q2 2022

Aug 12, 2022

SELL
$2.11 - $3.15 $1.28 Million - $1.91 Million
-606,518 Reduced 46.93%
685,749 $1.98 Million
Q1 2022

May 13, 2022

BUY
$3.0 - $4.88 $331,836 - $539,786
110,612 Added 9.36%
1,292,267 $3.88 Million
Q4 2021

Feb 11, 2022

SELL
$4.6 - $6.72 $26,068 - $38,082
-5,667 Reduced 0.48%
1,181,655 $5.44 Million
Q3 2021

Nov 12, 2021

BUY
$5.58 - $7.04 $150,643 - $190,058
26,997 Added 2.33%
1,187,322 $7.46 Million
Q2 2021

Aug 13, 2021

BUY
$5.19 - $6.73 $496,688 - $644,067
95,701 Added 8.99%
1,160,325 $6.95 Million
Q1 2021

May 12, 2021

BUY
$5.74 - $9.67 $521,972 - $879,351
90,936 Added 9.34%
1,064,624 $6.73 Million
Q4 2020

Feb 12, 2021

BUY
$5.3 - $6.71 $131,917 - $167,011
24,890 Added 2.62%
973,688 $5.48 Million
Q3 2020

Nov 13, 2020

SELL
$5.73 - $8.11 $184,683 - $261,393
-32,231 Reduced 3.29%
948,798 $5.52 Million
Q2 2020

Aug 13, 2020

BUY
$4.35 - $8.08 $61,400 - $114,049
14,115 Added 1.46%
981,029 $7.07 Million
Q1 2020

May 14, 2020

BUY
$3.45 - $7.95 $201,476 - $464,272
58,399 Added 6.43%
966,914 $4.53 Million
Q4 2019

Feb 13, 2020

BUY
$6.38 - $8.73 $769,836 - $1.05 Million
120,664 Added 15.32%
908,515 $7.29 Million
Q3 2019

Nov 12, 2019

BUY
$6.55 - $8.6 $311,452 - $408,930
47,550 Added 6.42%
787,851 $5.42 Million
Q2 2019

Aug 14, 2019

BUY
$7.67 - $10.63 $513,744 - $712,008
66,981 Added 9.95%
740,301 $6.14 Million
Q1 2019

May 14, 2019

BUY
$7.58 - $9.94 $597,379 - $783,371
78,810 Added 13.26%
673,320 $6.69 Million
Q4 2018

Feb 13, 2019

BUY
$7.16 - $16.21 $998,247 - $2.26 Million
139,420 Added 30.64%
594,510 $4.55 Million
Q3 2018

Nov 13, 2018

BUY
$9.7 - $19.65 $573,066 - $1.16 Million
59,079 Added 14.92%
455,090 $7.93 Million
Q2 2018

Aug 14, 2018

BUY
$3.88 - $12.74 $627,384 - $2.06 Million
161,697 Added 69.01%
396,011 $3.76 Million
Q1 2018

May 15, 2018

BUY
$4.11 - $6.93 $479,616 - $808,696
116,695 Added 99.21%
234,314 $1.02 Million
Q4 2017

Feb 13, 2018

BUY
$1.74 - $4.34 $150,257 - $374,780
86,355 Added 276.21%
117,619 $477,000
Q2 2017

Aug 14, 2017

BUY
N/A
31,264
31,264 $33,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.1B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.